Search
Showing results for "early lung health"
As a leading research site in Australia, the Wesfarmers Centre of Vaccines and Infectious Diseases played an instrumental role in the global effort to develop a world-first RSV immunisation for young babies.
On this Research Impact page, we list stories helping demonstrate how we collaborate with other leaders, innovators, communities, and international stakeholders to ensure excellent research results. The better our results, the better the chances of research making a real difference.
As well as ORIGINS long-term core research, there are a number of clinical trials, early interventions and shorter-term research studies that sit within ORIGINS. Known as sub-projects, these studies look at multiple aspects of child and family health and development.
Research
Reversible Control by Vitamin D of Granulocytes and Bacteria in the Lungs of Mice: An Ovalbumin-Induced Model of Allergic Airway DiseaseVitamin D may be essential for restricting the development and severity of allergic diseases and asthma, but a direct causal link between vitamin D...
Research
Estimating the Impact And Costs of Antimicrobial Resistance (AMR) at Perth Children’s HospitalAMR is a rapidly growing challenge and has been identified as one of the World Health Organizations top 10 global health threats, with the potential to undo many of the health gains observed over the last century.
Research
Research priorities for the primordial prevention of acute rheumatic fever and rheumatic heart disease by modifying the social determinants of healthThe social determinants of health such as access to income, education, housing and healthcare, strongly shape the occurrence of acute rheumatic fever and rheumatic heart disease at the household, community and national levels.
Research
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second boosterPICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
A decade long partnership with Wesfarmers Ltd. and the Wesfarmers Centre of Vaccines and Infectious Diseases has led to world-class paediatric research and important collaborations fuelling the Centre’s trajectory towards easing the burden of infectious diseases.
Research
Childhood pneumonia in the Eastern Highlands Province of Papua New Guinea: clinical, microbiological and immunological predictors of diseaseChristopher Deborah Hannah Lea-Ann Peter Blyth Lehmann Moore Kirkham Richmond MBBS (Hons) DCH FRACP FRCPA PhD AO, MBBS, MSc OAM BSc (Hons)
Dr Anthony Bosco, Professor Steve Stick, Professor Andrew Whitehouse, Dr Raelene Endersby and Dr Luke Garratt know how fortunate they are to have